Drug intelligence / Profile preview

MDI-0238

Development stage: Preclinical
Lead developer: Alivexis
Modality: Small Molecules

Overview

MDI-0238 (also known as MOD-B) is a small-molecule inhibitor of the KIT receptor tyrosine kinase, currently being developed by Alivexis, Inc. KIT is a critical regulator of mast cell survival, differentiation, and activation. By inhibiting KIT, MDI-0238 aims to reduce the number and activity of mast cells in tissues, providing a therapeutic approach for mast cell-driven allergic and inflammatory diseases. The drug is currently in the IND-enabling stage for multiple indications, including anaphylaxis, food allergies, chronic urticaria, asthma, and eosinophilic esophagitis. Preclinical models have demonstrated its efficacy in both acute and chronic mast cell-related conditions.

Other names: KIT inhibitor (Alivexis)

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on MDI-0238.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MDI-0238.

Explore the full profile